2:52 PM
 | 
Mar 08, 2018
 |  BC Extra  |  Company News

Sanofi turns infectious R&D over to Evotec

Sanofi (Euronext:SAN; NYSE:SNY) and Evotec AG (Xetra:EVT) partnered on Thursday to develop an infectious disease pipeline led by Evotec, seeded with more than 10 undisclosed early stage, preclinical assets from Sanofi's infectious disease portfolio excluding vaccines.

The companies said Evotec “will integrate” the pharma’s infectious disease research unit, which includes more than 100 employees, into its global drug...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >